On July 28, 2023 3H Pharmaceuticals reported that the preclinical research progress of the company’s first new generation highly selective inhibitor (Press release, 3H Pharmaceuticals, JUL 28, 2023, View Source [SID1234643970]). The project is going very smooth. It is expected to submit the IND to the United States in November and to submit the IND to China in December, and then will actively explore the IND in East Asian countries.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!